Human EGF R, His Tag (EGR-H5222) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 645 (Accession # P00533-1).
Predicted N-terminus: Leu 25
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 70.5kDa. The protein migrates as 95-120 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.
Human EGF R, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human EGF R, His Tag(Cat. No. EGR-H5222) was more than 90% and the molecular weight of this protein is around 90-115 kDa verified by SEC-MALS.
Immobilized Cetuximab at 2 μg/mL (100 μL/well) can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with a linear range of 0.006-0.025 μg/mL (QC tested).
Erbitux (Cetuximab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.3 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Loaded Erbitux (Cetuximab) on AHC Biosensor, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.23 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
2e5 of Anti-EGFR CAR-293 cells were stained with 100 μL of 1 μg/mL of Human EGF R, His Tag (Cat. No. EGR-H5222) and negative control protein respectively, washed and then followed by PE anti-His antibody and analyzed with FACS (Routinely tested).
Authors: E Zhukovsky, et al
Journal: US20190153104A1 2019
Authors: W Qiu, et al
Journal: Clin Dev Immunol 2019
Authors: Xinyue Hu, et al.
Journal: Mol Oncol 2018
Application: ELISA & SPR
Authors: Fazekas-Singer J, et al.
Journal: J Allergy Clin Immunol 2018
Application: Western Blot
Authors: Kahl M, et al.
Journal: Protein Expr Purif 2018
Authors: Fazekas-Singer J, et al.
Journal: Oncotarget 2017
Authors: Nath N, et al.
Journal: J Immunol Methods 2017
Authors: Yu X, et al.
Journal: J Immunol Methods 2016
Application: Cell-based assay
Authors: Kant S, et al.
Journal: Mol Microbiol 2015
Application: Assay for Enzyme Activity
Authors: Singer J, et al.
Journal: Mol Cancer Ther 2014
Authors: Olsen DA, et al.
Journal: Clin Chem Lab Med 2013
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.